Key result
Subsequent systemic anticancer therapy was the strongest factor determining longer survival after emergency intrapericardial cisplatin treatment.
Observational (n=17)
Answers are grounded in this paper and cite their sources.
May support intrapericardial cisplatin in recurrent malignant effusion; leaves open efficacy, dosing, and safety in prospective trials.
BACKGROUND: Pericardial effusion is associated with high mortality in oncology. The etiology of infectious pericarditis and iatrogenic effects of previous radio-/chemotherapy may be always suspected, especially when a subsequent episode is observed. PATIENTS AND METHODS: The study included 17 hemodynamically-unstable patients with cancer due to recurrent pericardial bloody effusion after previous pericardiocentesis and analyzed survival determinants after intrapericardial chemotherapy with cisplatin. RESULTS: /μl), large volume (>1500 ml) and long duration (>8 days) of pericardial drainage, cardiac arrhythmias, positive culture test results nor fever occurring during cisplatin administration. Subsequent systemic anticancer therapy was the strongest factor determining a longer survival (hazard ratio(HR)=0.31, 95% confidence interval(CI)=0.11-0.9; p=0.03). CONCLUSION: Efficacy of rescue intrapericardial chemotherapy with cisplatin is independent of parameters of hemodynamic instability and levels of inflammatory markers in recurrent pericardial effusion.
No takes yet. Share an insight, caveat, or question.
Darocha et al. (2018) conducted an observational in Cancer with recurrent pericardial bloody effusion (n=17). Subsequent systemic anticancer therapy was evaluated on Survival (HR 0.31, 95% CI 0.11-0.9, p=0.03). Subsequent systemic anticancer therapy was the strongest factor determining longer survival after emergency intrapericardial cisplatin treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: